# EDGAR Filing Document

**Accession Number:** 0001388325
**File Stem:** 0001388325-25-000004
**Filing Date:** 2025-9
**Character Count:** 11094
**Document Hash:** 8d67cfb9366342ebccbc403076c8053f
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001388325-25-000004.hdr.sgml**: 20250925

**ACCESSION NUMBER**: 0001388325-25-000004

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D/A

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20250925

**DATE AS OF CHANGE**: 20250925

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Galecto, Inc.
- **CENTRAL INDEX KEY:** 0001800315
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 371957007
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-91812
- **FILM NUMBER:** 251344433

**BUSINESS ADDRESS:**
- **STREET 1:** 75 STATE STREET
- **STREET 2:** SUITE 100
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02109
- **BUSINESS PHONE:** 45-70-70-52-10

**MAIL ADDRESS:**
- **STREET 1:** 75 STATE STREET
- **STREET 2:** SUITE 100
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02109

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Galecto Inc.
- **DATE OF NAME CHANGE:** 20200116
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Novo Holdings A/S
- **CENTRAL INDEX KEY:** 0001388325

**ORGANIZATION NAME:**
- **EIN:** 000000000
- **STATE OF INCORPORATION:** G7
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** TUBORG HAVNEVEJ 19
- **CITY:** HELLERUP
- **PROVINCE COUNTRY:** G7
- **ZIP:** 2900
- **BUSINESS PHONE:** 45 8824 8824

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** TUBORG HAVNEVEJ 19
- **CITY:** HELLERUP
- **PROVINCE COUNTRY:** G7
- **ZIP:** 2900

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Novo A/S
- **DATE OF NAME CHANGE:** 20070130

## Exhibit 99.1

EXHIBIT 99.1

SCHEDULE I

Information regarding each director and executive officer of both Novo Holdings A/S and the Novo Nordisk Foundation is set forth below.

**Novo Holdings A/S**

---

| | | | |
|:---|:---|:---|:---|
| **Name, Title** | **Address** | **Principal Occupation** | **Citizenship** |
| Lars Rebien Sørensen<br> Chair of the Board | Tuborg Havnevej 19<br> 2900 Hellerup<br> Denmark | Professional Board Director | Denmark |
| Steen Riisgaard<br> Vice Chair of the Board | Tuborg Havnevej 19<br> 2900 Hellerup<br> Denmark | Professional Board Director | Denmark |
| Torsten Sløk <br> Board Director  | Tuborg Havnevej 19<br> 2900 Hellerup<br> Denmark | Chief Economist of Apollo Global Management | USA<br> Denmark |
| Nirmal Prabhakar Narvekar<br> Board Director | Tuborg Havnevej 19<br> 2900 Hellerup<br> Denmark | CEO of Harvard Management Company | USA |
| Jun Sung Kim<br> Board Director | Tuborg Havnevej 19<br> 2900 Hellerup<br> Denmark | Head of the endowment fund for the National University of Singapore, and main board member of Samsung Electronics, Korea | Singapore |
| Francis Michael Cyprian Cuss<br> Board Director  | Tuborg Havnevej 19<br> 2900 Hellerup<br> Denmark | Biopharmaceutical Consultant  | United Kingdom |
| Viviane Monges<br> Board Director | Tuborg Havnevej 19<br> 2900 Hellerup<br> Denmark | Professional Board Director | France |
| Henrik Poulsen<br> Board Director | Tuborg Havnevej 19<br> 2900 Hellerup<br> Denmark | Senior Advisor, A.P. Møller Holding and Professional Board Director | Denmark |
| Britt Meelby Jensen<br> Board Director | Tuborg Havnevej 19<br> 2900 Hellerup<br> Denmark | Chief Executive Officer, <br> Ambu A/S | Denmark |
| Susanne Antonie Schaffert<br> Board Director | Tuborg Havnevej 19<br> 2900 Hellerup<br> Denmark | Professional Board Director | Germany |
| Lars Green,<br> Board Director | Tuborg Havnevej 19<br> 2900 Hellerup<br> Denmark | Professional Board Director | Denmark |
| Kasim Kutay<br> Chief Executive Officer | Tuborg Havnevej 19<br> 2900 Hellerup<br> Denmark | Chief Executive Officer, <br> Novo Holdings A/S | United Kingdom |
| Nigel Kevin Govett<br> Chief Financial Officer | Tuborg Havnevej 19<br> 2900 Hellerup<br> Denmark | Chief Financial Officer,<br> Novo Holdings A/S | United Kingdom |

---

------

**Novo Nordisk Foundation**

---

| | | | |
|:---|:---|:---|:---|
| **Name, Title** | **Address** | **Principal Occupation** | **Citizenship** |
| Lars Rebien Sørensen<br> Chair of the Board | Tuborg Havnevej 19<br> 2900 Hellerup<br> Denmark | Professional Board Director | Denmark |
| Lars Henrik Munch<br> Vice Chair of the Board | Tuborg Havnevej 19<br> 2900 Hellerup<br> Denmark | Professional Board Director | Denmark |
| Steen Riisgaard<br> Board Director  | Tuborg Havnevej 19<br> 2900 Hellerup<br> Denmark | Professional Board Director | Denmark |
| Lars Green<br> Board Director | Tuborg Havnevej 19<br> 2900 Hellerup<br> Denmark | Professional Board Director | Denmark |
| Barbara Casadei<br> Board Director | Tuborg Havnevej 19<br> 2900 Hellerup<br> Denmark | British Heart Foundation Professor of Cardiovascular Medicine, Honorary Consultant Cardiologist, and Head of the National Heart and Lung Institute at Imperial College London | Italy |
| Nana Bule Sejbaek<br> Board Director | Tuborg Havnevej 19<br> 2900 Hellerup<br> Denmark | Operating Advisor,<br> Goldman Sachs Asset Management and Professional Board Director | Denmark |
| Christopher Ashby Voigt<br> Board Director | Tuborg Havnevej 19<br> 2900 Hellerup<br> Denmark | Professor of Advanced Biotechnology and Department Head in Biological Engineering, Massachusetts Institute of Technology (MIT) | USA |
| Mads Boritz Grøn<br> Board Director | Tuborg Havnevej 19<br> 2900 Hellerup<br> Denmark | Quality Auditor,<br> Novo Nordisk A/S | Denmark |
| Ole Jakob Müller<br> Board Director | Tuborg Havnevej 19<br> 2900 Hellerup<br> Denmark | Senior Environmental Specialist,<br> Novonesis | Denmark |
| Stig Strøbaek<br> Board Director  | Tuborg Havnevej 19<br> 2900 Hellerup<br> Denmark | Electrician,<br> Novo Nordisk A/S | Denmark |
| Mads Krogsgaard Thomsen<br> Chief Executive Officer | Tuborg Havnevej 19<br> 2900 Hellerup<br> Denmark | Chief Executive Officer, <br> Novo Nordisk Foundation | Denmark |

---

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**(Amendment No. 4)**

**Galecto, Inc.**

*(Name of Issuer)*

**Common Stock, par value $0.00001 per share**

*(Title of Class of Securities)*

**36322Q107**

*(CUSIP Number)*

**Barbara Fiorini**<br>Novo Holdings A/S<br>Tuborg Havnevej 19<br>Hellerup G7 DK-2900<br>45 3527 6592

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**09/23/2025**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **36322Q107** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Novo Holdings A/S** | Name of reporting person<br>**Novo Holdings A/S** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**WC** | Source of funds (See Instructions)<br>**WC** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**G7** | Citizenship or place of organization<br>**G7** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**86579.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**86579.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**0.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**86579.00** | Aggregate amount beneficially owned by each reporting person<br>**86579.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**6.5%** | Percent of class represented by amount in Row (11)<br>**6.5%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**CO** | Type of Reporting Person (See Instructions)<br>**CO** | |

---

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Common Stock, par value $0.00001 per share

**(b) Name of Issuer:**
Galecto, Inc.

**(c) Address of Issuer's Principal Executive Offices:**
75 State Street, Suite 100, Boston, MA, 02109

This Amendment No. 4 (this "Amendment No. 4" or this "Schedule 13D/A") amends and supplements the statement on Schedule 13D originally filed with the Securities and Exchange Commission (the "SEC") on November 5, 2020, and amended on September 30, 2022, June 24, 2024 and January 16, 2025 (as amended, the "Statement") by Novo Holdings A/S. Unless otherwise defined herein, capitalized terms used in this Amendment No. 4 shall have the meanings ascribed to them in the Statement. Unless amended or supplemented below, the information in the Statement remains unchanged.

**Item 5. Interest in Securities of the Issuer**

**(a)**
Novo Holdings A/S beneficially owns 86,579 shares of Common Stock representing approximately 6.5% of the Issuer's outstanding shares of Common Stock, based upon 1,324,560 shares of the Common Stock outstanding as of August 1, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on August 5, 2025.

**(b)**
Novo Holdings A/S is a Danish corporation wholly owned by the Novo Nordisk Foundation. Novo Holdings A/S has the sole power to vote and dispose of the Novo Shares. Neither the Foundation nor any person listed on the updated Schedule I has the power to direct the vote as to, or the disposition of the Novo Shares.

**(c)**
Except as described below, Novo Holdings A/S has not effected any transactions in the Issuer's Common Shares within the past 60 days and neither the Foundation nor any person listed on the updated Schedule I has effected any transactions in the Issuer's Common Shares within the past 60 days.

On September 23, 2025, Novo Holdings A/S sold an aggregate of 13,334 shares of Common Stock in open market transactions at prices ranging from $4.00 to $4.85 (weighted average sales price of $4.2295 per share).

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Novo Holdings A/S

**Signature:** /s/ Barbara Fiorini

**Name/Title:** By Barbara Fiorini, General Counsel, Finance & Operations

**Date:** 09/25/2025